Digital health company DarioHealth Corp (NASDAQ:DRIO) said on Thursday that it has secured a clinical study contract for its B2B diabetes platform.
The company has signed the agreement with an undisclosed pharmaceutical company that is seeking US FDA clearance for a new drug related to managing diabetes. DarioHealth will run and track the blood glucose readings of participants in the clinical study via its B2B diabetes platform.
DarioHealth's B2B platform aims to increase user engagement during the course of the clinical study and will leverage key learnings from its direct-to-consumer success, including allowing the participants to log their BGM readings in real-time in the Dario logbook and utilise the reminders and statistics features.
This move into clinical studies and clinician practices shows the adoption of Dario Blood Glucose Monitoring System products and solutions going beyond the scope of just the consumer.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval